These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33486671)

  • 1. Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease.
    Signoriello E; Mallardo M; Nigro E; Polito R; Casertano S; Di Pietro A; Coletta M; Monaco ML; Rossi F; Lus G; Daniele A
    Mol Neurobiol; 2021 Jun; 58(6):2663-2670. PubMed ID: 33486671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis.
    Signoriello E; Lus G; Polito R; Casertano S; Scudiero O; Coletta M; Monaco ML; Rossi F; Nigro E; Daniele A
    Eur J Neurol; 2019 Feb; 26(2):348-355. PubMed ID: 30300462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.
    Wurth S; Kuenz B; Bsteh G; Ehling R; Di Pauli F; Hegen H; Auer M; Gredler V; Deisenhammer F; Reindl M; Berger T
    PLoS One; 2017; 12(8):e0182462. PubMed ID: 28777826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased Cerebrospinal Fluid Antioxidative Capacity Is Related to Disease Severity and Progression in Early Multiple Sclerosis.
    Voortman MM; Damulina A; Pirpamer L; Pinter D; Pichler A; Enzinger C; Ropele S; Bachmaier G; Archelos JJ; Marsche G; Khalil M
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572477
    [No Abstract]   [Full Text] [Related]  

  • 6. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
    Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
    Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologically active TGF-beta 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients.
    Rollnik JD; Sindern E; Schweppe C; Malin JP
    Acta Neurol Scand; 1997 Aug; 96(2):101-5. PubMed ID: 9272186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
    Albanese M; Zagaglia S; Landi D; Boffa L; Nicoletti CG; Marciani MG; Mandolesi G; Marfia GA; Buttari F; Mori F; Centonze D
    J Neuroinflammation; 2016 Feb; 13():36. PubMed ID: 26863878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients.
    Zeman D; Adam P; Kalistová H; Sobek O; Kelbich P; Andel J; Andel M
    Acta Neurol Scand; 2000 Feb; 101(2):89-94. PubMed ID: 10685854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset.
    Puthenparampil M; Federle L; Miante S; Zito A; Toffanin E; Ruggero S; Ermani M; Pravato S; Poggiali D; Perini P; Rinaldi F; Gallo P
    J Neuroinflammation; 2017 Jan; 14(1):11. PubMed ID: 28095856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
    Brettschneider J; Petzold A; Junker A; Tumani H
    Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Leurs CE; Podlesniy P; Trullas R; Balk L; Steenwijk MD; Malekzadeh A; Piehl F; Uitdehaag BM; Killestein J; van Horssen J; Teunissen CE
    Mult Scler; 2018 Apr; 24(4):472-480. PubMed ID: 28294696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
    Rejdak K; Eikelenboom MJ; Petzold A; Thompson EJ; Stelmasiak Z; Lazeron RH; Barkhof F; Polman CH; Uitdehaag BM; Giovannoni G
    Neurology; 2004 Oct; 63(8):1439-45. PubMed ID: 15505162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study.
    Hietaharju A; Kuusisto H; Nieminen R; Vuolteenaho K; Elovaara I; Moilanen E
    Eur J Neurol; 2010 Feb; 17(2):332-4. PubMed ID: 19538214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis.
    Koch M; Heersema D; Mostert J; Teelken A; De Keyser J
    Eur J Neurol; 2007 Jul; 14(7):797-800. PubMed ID: 17594338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica.
    Jiang Y; Yang Y; Zhang B; Peng F; Bao J; Hu X
    Neuro Endocrinol Lett; 2009 Mar; 30(1):85-90. PubMed ID: 19300400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry.
    Jasperse B; Jakobs C; Eikelenboom MJ; Dijkstra CD; Uitdehaag BM; Barkhof F; Polman CH; Teunissen CE
    J Neurol; 2007 May; 254(5):631-7. PubMed ID: 17415509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
    Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
    J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients.
    Hirotani M; Maita C; Niino M; Iguchi-Ariga S; Hamada S; Ariga H; Sasaki H
    Mult Scler; 2008 Sep; 14(8):1056-60. PubMed ID: 18632777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilaments and 10-year follow-up in multiple sclerosis.
    Bhan A; Jacobsen C; Myhr KM; Dalen I; Lode K; Farbu E
    Mult Scler; 2018 Sep; 24(10):1301-1307. PubMed ID: 30066611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.